Telemonitoring of Spirometry and Oximetry in Patients with Interstitial Lung Disease Associated with Connective Tissue Disorders: A Prospective Observational Cohort Analysis - Scorecard - MDSpire
Advertisement
Telemonitoring of Spirometry and Oximetry in Patients with Interstitial Lung Disease Associated with Connective Tissue Disorders: A Prospective Observational Cohort Analysis
Clinical Scorecard: Telemonitoring of Spirometry and Oximetry in Patients with Interstitial Lung Disease Associated with Connective Tissue Disorders: A Prospective Observational Cohort Analysis
At a Glance
Category
Detail
Condition
Interstitial Lung Disease (ILD) associated with Connective Tissue Disorders (CTD)
Key Mechanisms
Autoimmune multisystem inflammation causing pulmonary complications; monitoring via home spirometry (FVC, FEV1) and pulse oximetry (SpO2) to detect disease progression and exacerbations
Target Population
Adults with CTD-ILD (including RA, SSc, PM, DM, pSS, MCTD, UCTD) and idiopathic pulmonary fibrosis (IPF) as control
Care Setting
Home-based telemonitoring with remote data transmission to healthcare providers in tertiary referral centers
Key Highlights
Home spirometry correlates well with hospital spirometry and enables early detection of ILD progression and acute exacerbations.
Pulse oximetry is critical for monitoring hypoxemia, guiding oxygen supplementation decisions in ILD patients.
Challenges in home monitoring include impaired hand function and microstomia in CTD patients, and Raynaud’s phenomenon affecting SpO2 accuracy.
Guideline-Based Recommendations
Diagnosis
Diagnosis of CTD-ILD should follow ACR/EULAR and Alarcón-Segovia criteria for CTD and established ILD diagnostic criteria.
IPF diagnosis should follow ATS/ERS/JRS/ALAT guidelines or surgical lung biopsy confirmation.
Management
Use handheld spirometers linked to smartphone apps for weekly home monitoring of FVC and FEV1.
Employ finger or ear-clip pulse oximeters to monitor peripheral oxygen saturation regularly.
Provide alternative oximetry devices (ear-clip) for patients with Raynaud’s phenomenon to improve SpO2 accuracy.
Monitoring & Follow-up
Perform at least weekly spirometry maneuvers at consistent times, using the best daily value for analysis.
Transmit data securely and in real-time to healthcare providers for review.
Use patient-reported outcome measures (mMRC, LCQ, K-BILD, EQ-5D-3L) at baseline and 6 months to assess symptoms and quality of life.
Define successful adherence as >70% weekly monitoring compliance.
Risks
Potential for inaccurate spirometry readings due to microstomia limiting mouthpiece seal.
False low SpO2 readings in patients with Raynaud’s phenomenon due to impaired peripheral circulation.
Exclusion of patients without smartphone/internet access or life expectancy under 12 months limits applicability.
Patient & Prescribing Data
Patients with CTD-ILD and IPF participating in home monitoring programs
Home telemonitoring is feasible and acceptable, with adherence influenced by device usability and patient-specific challenges related to CTD manifestations.
Clinical Best Practices
Provide training and support to patients for device setup and use to enhance adherence.
Use Bluetooth-enabled spirometers linked to secure smartphone applications for real-time data sharing.
Offer alternative oximetry devices for patients with peripheral circulation issues to ensure accurate SpO2 readings.
Incorporate patient-reported outcome measures to complement physiological monitoring and guide clinical decisions.
